|
40 Companies |
|
48 Products |
|
48 Products |
|
0 Mechanisms of Action |
|
20 Trials |
|
419 News |
|
| «12345678» |
- New P1 trial: Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease (clinicaltrials.gov) - Jul 9, 2013
P1, N=32, Recruiting, Sponsor: Duke University
- New P1 trial: Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease (clinicaltrials.gov) - Jul 8, 2013
P1, N=20, Recruiting, Sponsor: University Hospital Case Medical Center
- Enrollment open: Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease (clinicaltrials.gov) - Jul 8, 2013
P1, N=20, Recruiting, Sponsor: University Hospital Case Medical Center
Not yet recruiting --> Recruiting
- Trial termination: VPACS: Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease (clinicaltrials.gov) - Jun 3, 2013
P=N/A, N=120, Terminated, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Recruiting --> Terminated; decision of the promoter
- Integrilin (eptifibatide) / Takeda
Trial termination: A Safety Study of Eptifibatide in Patients With Sickle Cell Disease (clinicaltrials.gov) - May 21, 2013
P1/2, N=13, Terminated, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Terminated; decision of the promoter Completed --> Terminated; Slow accrual and no cost extension not approved by NHLBI
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Enrollment open: A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) - May 12, 2013
P2, N=96, Recruiting, Sponsor: Dana-Farber Cancer Institute
Completed --> Terminated; Slow accrual and no cost extension not approved by NHLBI Not yet recruiting --> Recruiting
- || acetylcysteine solution / Generic mfg.
New P3 trial: N-Acetylcysteine in Patients With Sickle Cell Disease (clinicaltrials.gov) - May 6, 2013
P3, N=140, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Sanguinate (PEGylated Carboxyhemoglobin bovine) / Prolong Pharma
New P1 trial: Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients (clinicaltrials.gov) - May 6, 2013
P1, N=24, Recruiting, Sponsor: Prolong Pharmaceuticals
- Clinical: Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis (clinicaltrials.gov) - May 5, 2013
P=N/A, N=40, Recruiting, Sponsor: Ashutosh Lal
- Trial termination: Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia (clinicaltrials.gov) - Apr 29, 2013
P2, N=2, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Due to slow recruitment
- Enrollment change: Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia (clinicaltrials.gov) - Apr 29, 2013
P2, N=2, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Terminated; Due to slow recruitment N=20 --> 2
- propranolol / Generic mfg.
Enrollment change: Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD) (clinicaltrials.gov) - Apr 28, 2013
P2, N=27, Active, not recruiting, Sponsor: Laura M. De Castro
N=20 --> 2 N=40 --> 27
- propranolol / Generic mfg.
Enrollment closed: Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD) (clinicaltrials.gov) - Apr 28, 2013
P2, N=27, Active, not recruiting, Sponsor: Laura M. De Castro
N=40 --> 27 Recruiting --> Active, not recruiting
- Zyflo (zileuton) / Chiesi
Enrollment closed: Trial of Zileuton CR in Children and Adults With Sickle Cell Disease (clinicaltrials.gov) - Apr 21, 2013
P1, N=9, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- deferiprone / Generic mfg.
New P1 trial: Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease (clinicaltrials.gov) - Apr 17, 2013
P1, N=8, Not yet recruiting, Sponsor: ApoPharma
- Enrollment change: THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA) (clinicaltrials.gov) - Apr 15, 2013
P3, N=38, Terminated, Sponsor: New England Research Institutes
Recruiting --> Active, not recruiting N=278 --> 38
- ||||||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion: Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease (clinicaltrials.gov) - Apr 7, 2013
P3, N=158, Completed, Sponsor: Pfizer
N=278 --> 38 Recruiting --> Completed
- | Trial completion: Safety Study of MP4CO in Adult Sickle Cell Patients (clinicaltrials.gov) - Apr 2, 2013
P1, N=32, Completed, Sponsor: Sangart
Recruiting --> Completed Recruiting --> Completed
- Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
Trial completion: Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease (clinicaltrials.gov) - Mar 31, 2013
P1, N=39, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed Recruiting --> Completed
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment change: Sickle Cell Disease Conditioning for Bone Marrow Transplant (clinicaltrials.gov) - Mar 7, 2013
P1, N=24, Suspended, Sponsor: Emory University
Recruiting --> Completed N=18 --> 24
- Trial termination: Kidney Transplantation in Patients With Sickle Cell Disease (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=2, Terminated, Sponsor: Emory University
Completed --> Terminated; Only 1 patient was enrolled. No funding, small number of eligible patients so would not achieve statistical power.
- Enrollment change: Preventing Acute Chest Syndrome by Transfusion Feasibility Study (clinicaltrials.gov) - Feb 21, 2013
P=N/A, N=237, Completed, Sponsor: New England Research Institutes
No funding, small number of eligible patients so would not achieve statistical power. N=40 --> 237
- | New P2 trial: Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial (clinicaltrials.gov) - Feb 20, 2013
P2, N=56, Completed, Sponsor: Children's Hospital & Research Center Oakland
- Clinical: Cognitive Rehabilitation in Sickle Cell Disease (clinicaltrials.gov) - Feb 14, 2013
P=N/A, N=30, Recruiting, Sponsor: Duke University
- NKTT120 / NKT Therap
Enrollment open: Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) (clinicaltrials.gov) - Feb 12, 2013
P1, N=21, Recruiting, Sponsor: NKT Therapeutics
N=40 --> 237 Not yet recruiting --> Recruiting
- | Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
New P2 trial: A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) - Feb 7, 2013
P2, N=96, Recruiting, Sponsor: Dana-Farber Cancer Institute
- Campath (alemtuzumab) / Sanofi
Enrollment change: Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies (clinicaltrials.gov) - Feb 5, 2013
P2, N=2, Completed, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting N=20 --> 2
- | NKTT120 / NKT Therap
New P1 trial: Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) (clinicaltrials.gov) - Feb 3, 2013
P1, N=21, Recruiting, Sponsor: NKT Therapeutics
- |||||| vepoloxamer (MST-188) / Savara
Enrollment open: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (clinicaltrials.gov) - Jan 29, 2013
P3, N=388, Recruiting, Sponsor: Mast Therapeutics, Inc.
N=20 --> 2 Not yet recruiting --> Recruiting
- hydroxyurea / Generic mfg.
Enrollment change: Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease (clinicaltrials.gov) - Jan 29, 2013
P=N/A, N=62, Completed, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting N=100 --> 62
- hydroxyurea / Generic mfg.
Trial completion: Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease (clinicaltrials.gov) - Jan 29, 2013
P=N/A, N=62, Completed, Sponsor: Assistance Publique - H
N=100 --> 62 Recruiting --> Completed
- Campath (alemtuzumab) / Sanofi
Trial completion: Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes (clinicaltrials.gov) - Jan 8, 2013
P2, N=2, Completed, Sponsor: David Rizzieri
Recruiting --> Completed Active, not recruiting --> Completed
- Trial termination, Stroma: Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs (clinicaltrials.gov) - Dec 19, 2012
P2, N=6, Terminated, Sponsor: Stanford University
Active, not recruiting --> Completed Recruiting --> Terminated
- Enrollment change, Stroma: Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs (clinicaltrials.gov) - Dec 19, 2012
P2, N=6, Terminated, Sponsor: Stanford University
Recruiting --> Terminated N=35 --> 6
- morphine sulphate / Generic mfg., paracetamol / Generic mfg.
Trial completion: DREPANOX: Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=176, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=35 --> 6 Recruiting --> Completed
- | prasugrel / Generic mfg.
Trial completion: A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (clinicaltrials.gov) - Dec 11, 2012
P2, N=33, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed Recruiting --> Completed
- imatinib / Generic mfg., carvedilol / Generic mfg.
Trial withdrawal: Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease (clinicaltrials.gov) - Dec 11, 2012
P1, N=0, Withdrawn, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Completed Recruiting --> Withdrawn
- imatinib / Generic mfg., carvedilol / Generic mfg.
Enrollment change: Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease (clinicaltrials.gov) - Dec 11, 2012
P1, N=0, Withdrawn, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Withdrawn N=200 --> 0
- morphine sulphate / Generic mfg., ibuprofen / Generic mfg.
Trial termination: SWIM: Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & Morphine (clinicaltrials.gov) - Dec 2, 2012
P4, N=320, Terminated, Sponsor: North West London Hospitals NHS Trust
N=200 --> 0 Recruiting --> Terminated; The funding withdrawal and early termination of the trial is based upon lack of suitable recruitment figures in order to reach the required trial endpoints.
- hydroxyurea / Generic mfg.
Trial completion, Adherence: Adherence to Hydroxyurea in Children With Sickle Cell Anemia (clinicaltrials.gov) - Nov 29, 2012
P=N/A, N=31, Completed, Sponsor: Duke University
Recruiting --> Terminated; The funding withdrawal and early termination of the trial is based upon lack of suitable recruitment figures in order to reach the required trial endpoints. Active, not recruiting --> Completed
- |||||||||| vepoloxamer (MST-188) / Savara
New P3 trial: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) (clinicaltrials.gov) - Nov 28, 2012
P3, N=388, Recruiting, Sponsor: Mast Therapeutics, Inc.
- hydroxyurea / Generic mfg.
Enrollment change: State Of The Art Functional Imaging In Sickle Cell Disease (clinicaltrials.gov) - Nov 12, 2012
P=N/A, N=60, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed N=79 --> 60
- ||| Trial completion, Review: Sickle Cell Disease: A Retrospective Chart Review (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=261, Completed, Sponsor: Novartis Pharmaceuticals
N=79 --> 60 Recruiting --> Completed
- | Paludrine (proguanil) / Alliance
New P1/2 trial: The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia (clinicaltrials.gov) - Oct 8, 2012
P1/2, N=150, Completed, Sponsor: Lagos State University
- Enrollment change: Kidney Transplantation in Patients With Sickle Cell Disease (clinicaltrials.gov) - Oct 4, 2012
P=N/A, N=2, Terminated, Sponsor: Emory University
Recruiting --> Completed N=50 --> 2
- simvastatin / Generic mfg.
New P2 trial: Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease (clinicaltrials.gov) - Oct 4, 2012
P2, N=25, Recruiting, Sponsor: Children's Hospital & Research Center Oakland
- Lucentis (ranibizumab) / Roche, Novartis
Trial withdrawal: Ranibizumab for Neovascularization in Sickle Cell Retinopathy (clinicaltrials.gov) - Sep 24, 2012
P1, N=0, Withdrawn, Sponsor: Kresge Eye Institute
N=50 --> 2 Recruiting --> Withdrawn
- New P1 trial: Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease (clinicaltrials.gov) - Sep 12, 2012
P1, N=25, Recruiting, Sponsor: The Cleveland Clinic
- oxymorphone IR / Generic mfg.
Enrollment change: Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects (clinicaltrials.gov) - Aug 14, 2012
P3, N=0, Withdrawn, Sponsor: Endo Pharmaceuticals
Recruiting --> Withdrawn N=24 --> 0
- enalapril / Generic mfg.
Trial termination: MADREPIEC: Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children (clinicaltrials.gov) - Jul 24, 2012
P=N/A, N=5, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
N=24 --> 0 Recruiting --> Terminated; Not enough inclusions